Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde

Cancer Research

Volumn 60, Issue 16, 2000, Pages 4419-4425

  Steiner, M S ^a   Zhang, X ^a   Wang, Y ^a   Lu, Y ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; PROTEIN P53; PROTEIN PHYDE; UNCLASSIFIED DRUG;

ADENOVIRUS 5; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CONTROLLED STUDY; DNA HYBRIDIZATION; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; PHYDE GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; ROUS SARCOMA ONCOVIRUS; SUPPRESSOR GENE;

ADENOVIRUS E1 PROTEINS; ADENOVIRUS E3 PROTEINS; ADENOVIRUSES, HUMAN; AMINO ACID SEQUENCE; ANIMALS; APOPTOSIS; AVIAN LEUKOSIS VIRUS; DNA, COMPLEMENTARY; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GROWTH INHIBITORS; HUMANS; INTRINSIC FACTOR; MALE; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RATS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034662620     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Clinical evidence for and implications of the multistep development of prostate cancer
2. Chromosome abnormalities and related events in prostate cancer
3. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
4. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
5. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells
6. Modulation of oncogenic potential by alternative gene use in human prostate cancer
7. Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer
8. Inactivation of the tumor suppressor PTEN/MMACI in advanced human prostate cancer through loss of expression
9. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection
10. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: A preclinical study
11. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer
12. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells
13. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model
14. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
15. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
16. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: Activation of the vertebrate homologue of the Drosophila seven in absentia gene
17. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma
18. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo
19. Clinical phase I gene therapy trial using BRCA1 retrovirus is safe
20. Adenoviral vector containing wild type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
21. Application of an improved cDNA competition hybridization technique to identify prostate cancer associated gene
22. Role of pHyde novel gene product as an intrinsic factor for apoptotic pathway in prostate cancer
23. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5
24. Calcium phosphate transfection
25. Manipulation of adenovirus vectors
26. Analysis of RNA by Northern and Slot blot hybridization
27. Coexpression of galectin-1 and its complementary glycoconjugates laminin and lysosome-associated membrane proteins in murine PCC4.aza1R embryonal carcinoma cells induced to differentiation by butyrate
28. Differentiation induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines
29. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer
30. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
31. p53 Function and dysfunction
32. WAFl, a potential mediator of p53 tumor suppression
33. The p53-mdm-2 autoregulatory feedback loop
34. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
35. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
36. Cyclin G is a transcriptional target of the p53 tumor suppressor protein
37. Induction of the growth inhibitor IGF-binding protein 3 by p53
38. Transcriptional activation of the human proliferating cell nuclear antigen promoter by p53
39. Isolation of a novel GPI-anchored gene specifically regulated by p53: Correlation between its expression and anticancer drug sensitivity
40. Fas-mediated apoptosis in human prostatic carcinoma cell lines
41. Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
42. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer cancers
43. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells
44. Assessment of apoptosis in tumor growth: Importance in clinical oncology and cancer therapy
45. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
46. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: Implications for gene therapy